Candel Therapeutics (CADL) Restructuring Costs (2024 - 2025)
Candel Therapeutics' (CADL) quarterly Restructuring Costs came in at $479000.0 in Q4 2025, down 2.24% year-on-year from $490000.0 in Q4 2024, and up 8.13% quarter-over-quarter from $443000.0 in Q3 2025.
Candel Therapeutics (CADL) Restructuring Costs (2024 - 2025) Analysis & Trends
Candel Therapeutics has disclosed Restructuring Costs across 2 years of filings, most recently posting $479000.0 for Q4 2025.
- Restructuring Costs for Q4 2025 came in at $479000.0, down 2.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.8 million (down 5.86% YoY), and the FY2025 annual result was $1.8 million, down 5.86% from the prior year.
- Restructuring Costs came in at $479000.0 for Q4 2025 at Candel Therapeutics, up from $443000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $517000.0 in Q2 2024 to a low of $443000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Candel Therapeutics | 440.62 Mn | 440.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 479,000.00 |
| Sep 30, 2025 | 443,000.00 |
| Jun 30, 2025 | 462,000.00 |
| Mar 31, 2025 | 464,000.00 |
| Dec 31, 2024 | 490,000.00 |
| Sep 30, 2024 | 463,000.00 |
| Jun 30, 2024 | 517,000.00 |
| Mar 31, 2024 | 493,000.00 |